{"disease":{"id":"gallbladder-cancer-and-extrahepatic-cholangiocarcinoma","name":"gallbladder cancer and extrahepatic cholangiocarcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07007832","title":"Bile Omics for Diagnosing Indeterminate Biliary Strictures","phase":"","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06901622","title":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":50,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}